Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Post Schizophrenic Depression according to ICD10-DCR (International Classification of Diseases 10- Diagnostic Criteria for Research).~2. Aged between 18 to 60 years of either sex~3. Patients with a positive score of less than 29 on the Positive and Negative Syndrome Scale (PANSS) \[88\]~4. Patients with a score of more than 6 on the Montgomery-Asberg Depression Rating Scale (MADRS) \[89-90\]~5. Patients without Extrapyramidal symptoms: a score of less than 3 on the Simpson-Angus Scale \[91\]~6. With Informed consent from the Legally Authorised Relative~Exclusion Criteria:~1. Patients with a medical or neurological disorder~2. Patients with a history of substance dependence~3. Patients with high suicidality~4. Patients with a past history of primary depression~5. Patients already on Olanzapine-Fluoxetine combination or Amisulpride

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Amisulpride Group (Type: EXPERIMENTAL): The patients will receive low dose Amisulpride at 100-300 mg/day.
- Olanzapine-Fluoxetine Group (Type: ACTIVE_COMPARATOR): the patients will receive Olanzapine-Fluoxetine Combinations at 5/10 + 20 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).